TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04029428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 90Y-DOTATATE
Description: Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (177Lu-DOTAOTyr3)Octreotate
Description: Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
Description: Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
Study: NCT02518165

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proprietary spearmint extract
Description: Water extracted spearmint extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline Cellulose
Study: NCT00993863

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859 30 mg
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859 100 mg
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADL5859 200 mg
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 400 mg
Description: single dose
Study: NCT01457404

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy
Description: Individual or group ICBT, approx. 12 sessions, one session per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
Study: NCT04392674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the new tissue containment system
Description: using the new tissue containment system during Laparoscopic myomectomy morcellation
Study: NCT00647244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: Tenofovir disoproxil 245 mg oral tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir
Description: Abacavir 300 mg oral tablet twice daily
Study: NCT02072252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone Application
Description: Mobile phone app teaching cognitive behavioral skills
Study: NCT02947802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages
Description: In one of our parallel assigned conditions participants will receive additional information (e.g., an intervention) of effectiveness information. These consumers will learn how effective these labels were in reducing the purchasing of sugar sweetened beverages in a recent study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control condition
Description: In one of our parallel assigned conditions participants will receive no additional information and be asked to rate their support for the label.
Study: NCT03088644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: JNJ-54175446 up to 600 mg suspension for oral dose administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-JNJ-64413739
Description: 18F-JNJ-64413739 fluid for injection administered intravenously.
Study: NCT00804648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate in Sorbate
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate in Sorbate
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate in Sorbate
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate in Sorbate
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate in Sorbate
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol hemihydrate
Description: 0.5%
Study: NCT03088644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-JNJ-64413739
Description: 18F-JNJ-64413739 fluid for injection administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-JNJ-64413739
Description: 18F-JNJ-64413739 fluid for injection administered intravenously.
Study: NCT00804648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol hemihydrate
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol hemihydrate
Description: 0.5%
Study: NCT03026816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Cord Stimulation
Description: epidural spinal cord stimulator
Study: NCT01510990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: gefitinib 250mg/day daily
Study: NCT03863561

Intervention type: BEHAVIORAL
Intervention: Diabetes self-management education (DSME) program
Description: Diabetes educators customized care paths for their patients based on their individual responses to the SCPI questions. Patients met with an educator five to seven times over the course of three to four months.
Study: NCT01637532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab and interferon alpha 2-b
Description: During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab and interferon alpha 2-b
Description: During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin and Caelyx or doxorubicin
Description: Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Caelyx or doxorubicin
Description: Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Caelyx or doxorubicin
Description: Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
Study: NCT03122145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic swallow study
Description: The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videofluoroscopic swallow study
Description: The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic of the base of tongue, oropharynx, and hyolarynx complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
Study: NCT00804648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol hemihydrate
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol hemihydrate
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol hemihydrate
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate gel forming solution
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate gel forming solution
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate gel forming solution
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate gel forming solution
Description: 0.5%
Study: NCT02070328

Intervention type: OTHER
Intervention: Registry
Study: NCT03794427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unilateral lumbosacral nerve block
Description: Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo at the spinal anesthesia level
Description: Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo at lumbosacral level
Description: Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
Study: NCT04185077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
Study: NCT02783547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB C-1101 and Azacytidine
Description: This study is a multi-center open-label study to assess the tolerability of oral administration of SyB C-1101 twice daily from Day 1 to Day 21 in combination with subcutaneous administration or intravenous drip infusion of azacitidine once daily at a dose of 75 mg/m2 (body surface) for 7 days during the period between Day 8 and Day 16, and to estimate the recommended dose (RD) of C-1101.~SyB C-1101 will be administered at a daily dose of 560 mg or 840 mg in each of the 2 cohorts for a treatment period of 1 cycle for 28 days, including 21 days for SyB C-1101 treatment followed by 7 days of follow-up.
Study: NCT03238274

Intervention type: DEVICE
Intervention: Sofia 2 Lyme FIA testing
Description: IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody

Intervention type: DEVICE
Intervention: Sofia 2 Lyme FIA testing
Description: IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody

Intervention type: DEVICE
Intervention: Sofia 2 Lyme FIA testing
Description: IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
Study: NCT00939887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04455242
Description: Single dose of up to 30 mg PF-04455242, delivered in capsule.
Study: NCT03815448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
Study: NCT00804648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate gel forming solution
Description: 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol maleate gel forming solution
Description: 0.5%
Study: NCT03447496

Intervention type: PROCEDURE
Intervention: Closed reduction
Description: The children were treated with closed reduction.

Intervention type: PROCEDURE
Intervention: Open reduction
Description: The children were treated with Open reduction.
Study: NCT01807481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mircera
Description: Once Monthly Mircera
Study: NCT04512482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromelain
Description: The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bromelain
Description: The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powdered sugar
Description: The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Powdered sugar
Description: The subjects were randomized to either receive the bromelain pre-rinse or the powdered sugar placebo pre-rinse. Subjects then had a 5-9 day washout period and was then exposed to the other intervention.
Study: NCT01066767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Fexofenadine Hydrochloride 180 mg Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine Hydrochloride 180 mg Tablets
Study: NCT02509364

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT00322049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent live attenuated dengue vaccine
Description: DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.~Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.~All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.~A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent live attenuated dengue vaccine
Description: DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.~Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.~All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.~A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine
Description: Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
Study: NCT00773851

Intervention type: PROCEDURE
Group type: OTHER
Intervention: mesh fixation by transfacial sutures
Description: mesh fixation by transfacial sutures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: mesh fixation by staples
Description: mesh fixation by staples
Study: NCT03609489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
Study: NCT00960791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral single dose
Study: NCT01152125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow stem cells
Description: Stem cells isolated from the patient's own bone marrow.
Study: NCT03609489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, 500 mg, administered orally (after breakfast) once daily from day 1 to day 21 (including day 21) with continuous administration. Every 21 days serve as a cycle. If after 2 dose adjustments, the subject is still unable to tolerate toxicity, he/she should be moved out of the group.
Study: NCT03354572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl cysteine
Description: acetyl cysteine 150 mg/kg prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: saline 0.9% prior to surgery
Study: NCT01719679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Located Vaccine (SLV) Program
Description: A community vaccinator will administer vaccines to students whose parents consent for their child to participate
Study: NCT01332097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCT197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCT197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCT197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCT197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone placebo
Description: capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone placebo
Description: capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BCT197 placebo
Description: capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCT197 placebo
Description: capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: capsules
Study: NCT00710567

Intervention type: DEVICE
Group type: OTHER
Intervention: DuraHeart Left Ventricular Assist System (LVAS)
Description: The DuraHeart LVAS is implanted in using open heart surgery